AIxCrypto: From Cancer Labs to Crypto Flywheels
TL;DR
Quick Summary
- Qualigen Therapeutics is rebranding as AIxCrypto Holdings ($AIXC) after shareholder approval on November 16, 2025, with Faraday Future ($FFAI) taking majority control.
- The company is pivoting from biotech to an AI × Web3 platform built around the C10 crypto treasury and index, the BesTrade DeAI Agent, and new tokens/RWA products.
- A $41M PIPE financing, a $50M AUM target for the C10 Treasury by end‑2025, and near‑term launches (BesTrade beta, token whitepaper) make $AIXC a high‑risk, high‑catalyst crypto proxy.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
